EMA Authorised: Exelon (rivastigmine) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Exelon (rivastigmine) for dementia including Alzheimer's disease and Parkinson's disease, with Novartis Europharm Limit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Exelon (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Novartis Europharm Limited. Decision date: 23/02/2026